with the advent of revolutonary gene therapy drugs for patient disease mangement, we are happy to launch the following -
KRIBIOLISA™ Anti-AAV5 ELISA
KRIBIOLISA™ Anti-AAV1 ELISA
KRIBIOLISA™ Anti-AAV2 ELISA
KRIBIOLISA™ Anti-AAV6 ELISA
KRIBIOLISA™ Anti-AAV8 ELISA
KRIBIOLISA™ Anti-AAV9 ELISA
KRIBIOLISA™ Anti-AAV ELISA
These assays measure the immunogenicity - antibodies generated against specific Adeno Associated Virus subtypes and also total AAV.
Gene therapy vectors using AAV can infect both dividing and quiescent cells and persist in an extrachromosomal state without integrating into the genome of the host cell, although in the native virus some integration of virally carried genes into the host genome does occur. The advantages of AAV make them a very attractive candidate for creating viral vectors for gene therapy, and for the creation of isogenic human disease models. Recent human clinical trials using AAV for gene therapy in the retina have shown promise.
to date, AAV vectors have been used in over 117 clinical trials worldwide, approximately 5.6% of virus-vectored gene-therapy trials. Recently, promising results have been obtained from Phase 1 and Phase 2 trials for a number of diseases, including Leber's congenital amaurosis, Hemophilia, congestive heart failure, spinal muscular atrophy, lipoprotein lipase deficiency and Parkinson's disease.
Our assay kits help in measuring the imunogenicity associated with these therapies.
Exhibitor Data Sheet